Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Efficacy and safety results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial
Journal article published in 2018 by
Alexander M. Eggermont,
Christian U. Blank,
Mario Mandala,
Georgina Long,
Victoria Atkinson,
Stephane Dalle,
Andrew Haydon,
Mikhail Lichinitser,
Adnan Khattak,
Matteo S. Carlino 
